(Q39860917)

15 September 2017

title

Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons (English)

1 reference

15 September 2017

1 reference

1

1 reference

15 September 2017

Calogero Cammà

2

1 reference

15 September 2017

publication date

1 July 2010

1 reference

Digestive and Liver Disease

15 September 2017

published in

1 reference

15 September 2017

volume

42 Suppl 3

1 reference

15 September 2017

page(s)

S287-92

1 reference

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Prevention of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

[Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized, multicenter study]

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

Retinoids in cancer chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2810%2960518-X

7 January 2021

10.1016/S1590-8658(10)60518-X

Identifiers

DOI

1 reference

15 September 2017

1 reference